FDA clinical trials
In the past months we’ve seen the approval of several drugs with limited data. Possibly this is the ‘natural’ consequence of both the Fast Track Designation and the Adaptative Pathway solutions that have been accepted.
Category: pharma
Assessing the Value of New Antibiotics
Dr. Solà-Morales Serra has participated in the formulation of a new study called, Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions.
Drug’s public procurement study
Dr. Solà-Morales Serra has participated in the formulation of a new study that explains the innovative approach of drug’s public procurement.
Unacceptable untreated Pain: time for action
I had yesterday a very interesting discussion about pain and pain treatment, why is it accepted to have a certain level of pain and what to do to improve untreated pain. In the United States, in 2011 the annual cost of untreated pain is reported to be between US$560–US$635 billion[1]. The discussions were about drugs, drug interactions, side effects, convenience, adherence, patient preferences and even about culture and religious beliefs.